Michael L Johnson
Overview
Explore the profile of Michael L Johnson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
186
Citations
2479
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Anyanwu P, Olateju O, Tata V, Varisco T, Gilbert L, Ogunsanya M, et al.
Harm Reduct J
. 2024 Dec;
21(1):220.
PMID: 39707438
Introduction: Despite the established effectiveness and relatively widespread availability of Medications for Opioid Use Disorder, individuals seeking treatment frequently encounter various structural and social barriers, including costs of treatment. This...
2.
Majd Z, Chen H, Johnson M, Birtcher K, Serna O, Abughosh S
J Am Pharm Assoc (2003)
. 2024 Nov;
65(1):102295.
PMID: 39536802
Background: Despite evidence-based guidelines and available therapies, many patients with type 2 diabetes (T2D) have suboptimal glycemic control. The current standard of care suggests initial monotherapy followed by add-on therapy...
3.
Gohil S, Chen H, Lewis W, Trivedi M, Aparasu R, Johnson M
J Geriatr Oncol
. 2024 Sep;
15(8):102071.
PMID: 39312847
Introduction: The presence of pre-existing autoimmune disease (PAD) with metastatic non-small cell lung cancer (mNSCLC) poses challenges in the use of immune checkpoint inhibitors (ICI). This study investigated factors influencing...
4.
Goyal R, Candrilli S, Abughosh S, Chen H, Holmes H, Johnson M
Cancers (Basel)
. 2024 Jun;
16(12).
PMID: 38927874
In hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC), cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) have replaced endocrine therapy alone as the standard of care; however, several...
5.
Tabassum M, Chikermane S, Johnson C, Abdulkareem N, Wang E, Johnson M, et al.
Cardiooncology
. 2024 Mar;
10(1):17.
PMID: 38532523
Background: Cardiovascular (CV) disease is a leading cause of death in breast cancer (BC) patients due to the increased age and treatments. While individual β-blockers have been investigated to manage...
6.
Majd Z, Mohan A, Fatima B, Johnson M, Essien E, Abughosh S
Patient Educ Couns
. 2023 Dec;
119:108073.
PMID: 38039785
Objectives: To assess the impact of student telephone motivational interviewing intervention on angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (ACEI/ARBs) adherence trajectories and identify predictors of each trajectory. Methods: The intervention group included...
7.
Huang Y, Agarwal S, Chen H, Chatterjee S, Johnson M, Aparasu R
Clin Ther
. 2023 Aug;
45(9):e177-e186.
PMID: 37573225
Purpose: Guidelines recommend using disease-modifying antirheumatic drugs (DMARDs) in combination with methotrexate (MTX) for patients with rheumatoid arthritis (RA) after monotherapy. Little is known about the real-world comparative effectiveness of...
8.
Huang Y, Agarwal S, Chatterjee S, Chen H, Johnson M, Aparasu R
Clin Rheumatol
. 2023 Aug;
43(1):103-116.
PMID: 37540382
Objective: This study examined the risk of cardiovascular disease (CVD) associated with the disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA). Method: This nested case-control study used the MarketScan database...
9.
Huang Y, Chatterjee S, Agarwal S, Chen H, Johnson M, Aparasu R
Explor Res Clin Soc Pharm
. 2023 Jul;
11:100296.
PMID: 37521021
Background: Advances in Disease-Modifying Antirheumatic Drugs (DMARDs) have expanded the treatment landscape for Rheumatoid Arthritis (RA). Guidelines recommend adding either conventional synthetic (cs), biologic (b), or targeted synthetic (ts) DMARDs...
10.
Earla J, Li J, Hutton G, Johnson M, Aparasu R
Pharmacotherapy
. 2023 May;
43(6):473-484.
PMID: 37157135
Study Objective: This study compared the adherence trajectories of fingolimod (FIN), teriflunomide (TER), and dimethyl fumarate (DMF) users with multiple sclerosis (MS) as there is limited evidence regarding the comparative...